Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Active, not recruiting Phase 3 Interventional

ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors

ClinicalTrials.gov ID: NCT05671510

Public ClinicalTrials.gov record NCT05671510. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 3, 2026, 3:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers That Progressed on PD-1/PD-L1 Inhibitors

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The goal of this Phase 3 clinical trial is to study the safety and efficacy of the nextgen anti-CTLA-4 antibody, gotistobart (ONC-392/BNT316), in patients with metastatic non-small cell lung cancer who have disease progressed on anti-PD-1/PD-L1 antibody based therapy. The study will test whether gotistobart, in comparison with chemotherapy agent docetaxel, could prolong the life for NSCLC patients. Patients will be randomized to be treated with either gotistobart or docetaxel, IV infusion, once every 21 days, for up to 17 cycles in approximately one year.

Study identification

NCT ID
NCT05671510
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
OncoC4, Inc.
Industry
Enrollment
630 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 27, 2023
Primary completion
Aug 30, 2027
Completion
Aug 30, 2028
Last update posted
Aug 12, 2026

2023 – 2028

United States locations

U.S. sites
46
U.S. states
20
U.S. cities
45
Facility City State ZIP Site status
XCancer/Dothan Hematology & Oncology - 1114 Dothan Alabama 36303
Genesis Cancer and Blood Institute - 1123 Russellville Arkansas 72801
The Oncology Institute (TOI) Clinical Research - 1109 Cerritos California 90703
Emad Ibrahim MD Inc. - 1147 Redlands California 92373
UC Davis Comprehensive Cancer Center - 1103 Sacramento California 95817
Bass Medical Group - 1155 Walnut Creek California 94598
Nuvance Health - 1118 Norwalk Connecticut 06850
D&H Cancer Research Center LLC - 1153 Margate Florida 33063
Ocala Oncology Center PL - 1102 Ocala Florida 34474
AdventHealth Cancer Institute - 1105 Orlando Florida 32804
Orlando Health - 1130 Orlando Florida 32806
Florida Cancer Specialists -South - 1126 Sarasota Florida 34232
Florida Cancer Specialists -North - 1125 The Villages Florida 32159
Florida Cancer Specialists -East - 1124 West Palm Beach Florida 33401
Orchard Healthcare Research, Inc. - 1116 Skokie Illinois 60077
Springfield Clinic - The Cancer Center - 1110 Springfield Illinois 62702
Fort Wayne Medical Oncology - 1133 Fort Wayne Indiana 46805
Deaconess Chancellor Center for Oncology - 1131 Newburgh Indiana 47630
Cotton O'Neil Clinical Research Center - 1151 Topeka Kansas 66606
University of Kentucky - Markey Cancer Center - 1112 Lexington Kentucky 40536
Norton Cancer Institute - 1108 Louisville Kentucky 40202
Jefferson City Medical Group - 1145 Jefferson City Missouri 65109
MidAmerica Cancer Care - 1163 Kansas City Missouri 64132
Astera Cancer Care - 1128 East Brunswick New Jersey 08816
Duke University Medical Center - 1158 Durham North Carolina 27710
Miami Valley Hospital - 1115 Centerville Ohio 45459
University of Cincinnati Cancer Center - 1107 Cincinnati Ohio 45219
The Ohio State University James Cancer Center - 1104 Columbus Ohio 43210
Tri County Hematology & Oncology Associates, Inc - 1156 Massillon Ohio 44646
Oklahoma Cancer Specialists and Research Institute - 1154 Tulsa Oklahoma 74146
Oncology Associates of Oregon - 1138 Eugene Oregon 97401
St. Luke's University Health Network - 1179 Bethlehem Pennsylvania 18015
Donald Guthrie Foundation - 1135 Sayre Pennsylvania 18840
Cancer Care Associates of York, Inc. - 1113 York Pennsylvania 17403
University of Tennessee Medical Center - 1146 Knoxville Tennessee 37920
Sarah Cannon Research Institute - Tennessee Oncology at Nashville - 1119 Nashville Tennessee 37203
Texas Oncology - Baylor Charles A. Sammons Cancer Center (USOR) - 1140 Dallas Texas 75246
Texas Oncology - Denison - 1139 Denison Texas 75020
Oncology Consultants, P.A. - 1120 Houston Texas 77024
Oncology and Hematology of South Texas - 1165 Laredo Texas 78041
Texas Oncology - McAllen - 1132 McAllen Texas 78503
Texas Oncology -San Antonio - 1122 San Antonio Texas 78240
NEXT Oncology - Virginia - 1129 Fairfax Virginia 22031
Virginia Cancer Institute - 1149 Henrico Virginia 23226
Virginia Oncology Associates - 1136 Norfolk Virginia 23502
West Virginia University Cancer Institute - 1172 Morgantown West Virginia 26505

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 106 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05671510, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 12, 2026 · Synced Sep 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05671510 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →